SURVIVAL OF NONCURATIVELY RESECTED LUNG-CANCER

被引:15
|
作者
KIMURA, H [1 ]
YAMAGUCHI, Y [1 ]
机构
[1] CHIBA UNIV, SCH MED, INT PULM CANC RES, DEPT SURG, CHUO KU, CHIBA 260, JAPAN
关键词
LUNG CANCER; CURATIVITY; SURGERY; NONCURATIVE RESECTION; ADJUVANT THERAPY;
D O I
10.1016/0169-5002(94)90543-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Out of 858 patients who underwent thoracotomy for primary lung cancer, 279 cases were classified as non-curative on the basis of intraoperative and/or post-operative examinations. The causes for non-curative resection were defined as follows: (I) absolutely non-curative resection, (1) palliative tumor extirpation (palliative), (2) remaining tumor in (a) lymph nodes (Ly rem), (b) chest wall or diaphragm (Ch/Dia rem), or (c) bronchial stump (Pro rem), (3) intrapulmonary metastasis (PM), (4) pleural dissemination or pleuritis carcinomatosa (Pl/Diss), (5) metastasis in other organs (Meta); (II) relatively non-curative resection, (1) incomplete resection of lymph nodes (RO-1), (2) group 2b or 3 lymph node metastasis (2b Ly). The 5-year actuarial survival rate of the Pro rem group was 35.6%, being the best among the absolutely non-curative cases, followed by the PM group (33.7%), the Pl/Diss group (31.6%) and the Ch/Dia rem group (29.7%). The results of the Ly rem and Meta groups were poor at 5.4% and 0%, respectively. Those of the relatively non-curative group were 24.4% (RO-1 group) and 11.6% (2b Ly group). Non-curative resection is not the treatment of choice, but by analyzing the causes of non-curative resection, we may able to improve the prognosis of advanced cases of lung cancer.
引用
收藏
页码:229 / 242
页数:14
相关论文
共 50 条
  • [31] SERIAL IMMUNE TESTING IN SURGICALLY RESECTED LUNG-CANCER PATIENTS
    BRAUN, DP
    NISIUS, S
    HOLLINSHEAD, A
    HARRIS, JE
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1983, 15 (02) : 114 - 120
  • [32] BESTATIN IN RESECTED LUNG-CANCER - A RANDOMIZED CLINICAL-TRIAL
    YASUMITSU, T
    OHSHIMA, S
    NAKANO, N
    KOTAKE, Y
    TOMINAGA, S
    ACTA ONCOLOGICA, 1990, 29 (06) : 827 - 831
  • [33] LEU-7 IMMUNOREACTIVITY ON RESECTED MATERIAL OF LUNG-CANCER
    NAKAMURA, S
    ACTA HISTOCHEMICA ET CYTOCHEMICA, 1985, 18 (06) : 658 - 658
  • [34] RADIATION MYELITIS AND SURVIVAL IN THE RADIOTHERAPY OF LUNG-CANCER
    DISCHE, S
    WARBURTON, MF
    SAUNDERS, MI
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1988, 15 (01): : 75 - 81
  • [35] EFFECT OF SMOKING ON SURVIVAL OF PATIENTS WITH LUNG-CANCER
    LINDEN, G
    MANN, M
    HOM, PH
    DUNN, JE
    CANCER, 1972, 30 (02) : 325 - &
  • [36] LUNG-CANCER - SURGERY AND SURVIVAL - BORRIE,J
    RAVEN, RW
    ROYAL SOCIETY OF HEALTH JOURNAL, 1965, 85 (05): : 377 - 377
  • [37] SMOKING HISTORY AND LUNG-CANCER SURVIVAL IN WOMEN
    HINDS, MW
    YANG, HY
    STEMMERMANN, G
    LEE, J
    KOLONEL, LN
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1982, 68 (03) : 395 - 399
  • [38] INVITRO MONOCYTE MATURATION AND SURVIVAL IN LUNG-CANCER
    DENT, RG
    COLE, P
    THORAX, 1981, 36 (03) : 229 - 229
  • [39] RACIAL SURVIVAL PATTERNS FOR LUNG-CANCER IN HAWAII
    NOMURA, A
    KOLONEL, L
    RELLAHAN, W
    LEE, J
    WEGNER, E
    CANCER, 1981, 48 (05) : 1265 - 1271
  • [40] PROLONGED SURVIVAL AFTER RESECTION FOR LUNG-CANCER
    JACKSON, CA
    THORAX, 1974, 29 (05) : 612 - 612